Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 8/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.48 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706249 | 0.82 | MAPT (0.67) | KDM4EHPGDGAAMAPTRAB9A | |
| SCHEMBL1706301 | 0.78 | SMN1; SMN2 (0.51) | MAPTRAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL22134947 | 0.78 | KDM1A (0.49) | KDM4EHPGDGAAMAPTRAB9A | |
| Hydrochloric Acid SCHEMBL13517466 | 0.77 | SMN1; SMN2 (0.50) | MAPTRAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL29569079 | 0.75 | MAPT (0.57) | GAAMAPTKMT2ANPC1 | |
| SCHEMBL12993921 | 0.75 | MAPT (0.57) | GAAMAPTKMT2ANPC1 | |
| SCHEMBL8962169 | 0.72 | LTA4H (0.63) | MAPTRAB9AL3MBTL1KMT2ANPC1 | |
| SCHEMBL24653613 | 0.72 | MAPT (0.54) | KDM4EHPGDGAAMAPTRAB9A | |
| SCHEMBL31151862 | 0.72 | NPC1 (0.58) | KDM4EHPGDGAAMAPTRAB9A | |
| SCHEMBL49791 | 0.72 | NPC1 (0.58) | KDM4EHPGDGAAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | claimed |
| EP-2440547-B1 | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | ABIVAX (FR) | 2022-11-30 | — | — | EP | claimed |
| CN-105530938-B | Compounds for the treatment of diseases caused by retroviruses | ABIVAX公司 | 2019-10-22 | — | — | CN | claimed |
| EP-3517534-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-07-31 | — | — | EP | claimed |
| US-10017498-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2018-07-10 | — | — | US | claimed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | claimed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3016656-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-05-11 | — | — | EP | claimed |
| CN-105530938-A | Compounds for the treatment of diseases caused by retroviruses | ABIVAX | 2016-04-27 | — | — | CN | claimed |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-29 | — | — | US | claimed |
| WO-2015001518-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | SPLICOS (FR) | 2015-01-08 | — | — | WO | claimed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | claimed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | claimed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | claimed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | claimed |
| EP-2440545-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| EP-2440546-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| WO-2010143169-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| WO-2010143168-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| WO-2010143170-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017498-B2 | Compounds useful for treating AIDS | NR1H3, NR1H2, NR1H4 | KDM4E 3991/4885HPGD 1604/4885GAA 2756/4885 |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR1, CNR1, CBR3 | KDM4E 3299/4885HPGD 730/4885GAA 4565/4885 |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CBR1, CBR3, NCOR1 | KDM4E 2650/4885HPGD 984/4885GAA 4843/4885 |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | NR2C2, NCOR2, NR4A2 | KDM4E 3675/4885HPGD 772/4885GAA 3505/4885 |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | NR1H3, NR1H2, NR1H4 | KDM4E 3991/4885HPGD 1604/4885GAA 2756/4885 |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | RCOR1, CBR1, RCOR3 | KDM4E 2880/4885HPGD 2607/4885GAA 4514/4885 |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | KDM4E 3883/4885HPGD 1680/4885GAA 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.